Glaucoma is an eye disease that can lead to a permanent loss of vision. Glaucoma generally provides no warning signs or symptoms of disease, making testing an important part of a full vision exam.
Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which causes loss of vision. Abnormally high pressure inside your eye (intraocular pressure) usually, but not always, causes this damage.
Glaucoma is the second leading cause of blindness. Sometimes called the silent thief of sight, glaucoma can damage your vision so gradually you may not notice any loss of vision until the disease is at an advanced stage. The most common type of glaucoma, primary open-angle glaucoma, often has no noticeable signs or symptoms.
Early diagnosis and treatment can minimize or prevent optic nerve damage and limit glaucoma-related vision loss. It's important to get your eyes examined regularly, and make sure your eye doctor measures your intraocular pressure.
Two Injectable Stents. One Incredible Game-changer.
iStent inject® is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild-to-moderate primary open-angle glaucoma. Key advantages to using the device during cataract surgery include:
With iStent infinite ®, a trabecular micro-bypass device from Glaukos, Dr. Ehrenhaus can reduce IOP (intraocular pressure) in cases of open-angle glaucoma where previous medical and surgical interventions have failed. As one of the smallest implantable devices for the human body, iStent infinite ®, restores the eye’s natural ability to drain fluid and reduce IOP.
An advanced alternative to more invasive and compliance-dependent treatment
This innovative technology represents the latest advancements in care and offers the first micro-invasive and standalone implantable option to address patient non- compliance issues and disease progression.
When strategically placed via a precision-engineered injector system, iStent infinite® stents improve IOP control and reduce a patient’s dependence on glaucoma medication.
iStent inject® creates two patent bypass pathways through the trabecular meshwork—the main source of resistance for aqueous outflow—resulting in multi-directional flow through Schlemm’s canal. And it is the smallest medical device known to be implanted in the human body. Together, these unique advantages are designed to provide exceptional results in a truly micro-invasive approach.
With iStent inject®, two multi-directional stents are placed two to three clock hours apart. Together, they are designed to deliver access to multiple collector channels and arcs of flow that can span five to six clock hours. iStent inject® may also re-establish flow in previously dormant outflow channels.3
Putting the primary emphasis on maximizing benefits and minimizing long-term complications, iStent inject® is designed to support optimal outcomes after cataract surgery. In both the US pivotal study and worldwide commercial use, iStent inject® is proven to have an excellent safety profile, comparable to cataract surgery alone. It also offers much more:
The iStent inject® System is engineered to provide an enhanced surgical experience and ensure confident delivery, for every procedure. From the proprietary stent design to the streamlined injector system, iStent inject® was designed to be straightforward in use, precise in placement, and predictable in performance.
